Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the second quarter of 2019 on August 5, 2019 after the close of the financial markets.
Rimidi, a cloud-based software platform that enables personalized management of chronic cardiometabolic conditions across populations, today announced it has added a new disease ‘view’ to its platform. Joining its type 2 diabetes, heart failure and nonalcoholic fatty liver views, the software will now support cardiovascular disease (CVD).
#rpm
One Drop’s wireless blood glucose monitor is now being sold in certain US Apple Stores, according to a release from the company. One Drop’s platform, which is integrated with Apple’s Health Records, allows iPhone users to more conveniently check their glucose levels and share that data, alongside the rest of their personal health record, with providers. Additionally, purchase of the system at an Apple Store comes with a one-year subscription to the company’s companion app-based service.
#bgm
#mobile app
Gone are the days of endless finger pricks to test blood glucose levels and complicated mental calculations to deduce carbohydrate ratios with insulin. The growth of people with diabetes by 314 million in the last 34 years has created an ever-expanding market in diabetes management products. Consumers are now inundated with new technology streamlining lives with less needles and more real-time data to ensure immediate and precise responses to blood sugar levels. With all the different options, here are three popular tools that find the middle ground between breakthrough technology and user-friendly interfaces.
Diabetes management startup Pops! Diabetes Care has scored $6 million in an oversubscribed Series A round. The round was led by 30Ventures with participation from Rise of the Rest Seed Fund and Flying Point Industries.
The company's executives lauded the CGM system, which saw a 72.9% increase in organic sales during the last quarter, and hinted at implementations of the tech beyond diabetes alone. Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning.
#cgm
After much speculation and anticipation, chronic care management startup Livongo officially went public on Thursday. The company closed its first day 36% above its initial pricing of $28 and is currently trading for over $41 per share on NASDAQ. The company's includes more than 12 million shares of common stock.
Hello Heart, maker of a digital chronic disease health program for employees, has raised $12 million in Series B funding. The round was led by Khosla Ventures, with additional support from previous backers BlueRun Ventures, Maven Ventures and Resolute Ventures. The company also branched out into diabetes management in 2018, adding blood sugar tracking tools alongside new personalized prompts designed to drive healthy behavior change
The Group continued to enhance the capabilities of its Insulia product and work toward regulatory milestones. Voluntis has obtained CE marking for the new version of Insulia, which incorporates NPH (human) insulin. This version is being reviewed by the FDA in the United States, where the rising cost of insulin treatment has become a major public health issue. The first results from real-world Insulia patients confirm increasing consumer engagement and adherence to treatment recommendations. In addition, qualitative data showed a high level of satisfaction. In oncology, Voluntis has finalized the development of its multicancer symptom management solution and reaffirms its ambition to be able to launch its product in the second half of 2019. Voluntis’ Theraxium oncology platform and expertise are increasingly recognized by pharmaceutical companies and the Group is actively working to establish new partnerships.
#dtx
BD (Becton, Dickinson and Company) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019, at 8:00 a.m. (ET). BD will issue a press release detailing the quarter's earnings earlier that morning.